Abstract: Anthrax is one of the deadly infectious disease as documented in the CDC website. In spite of the availability of appropriate antimicrobial agents, the mortality related with the anthrax remains high. The pathogenicity of B.anthracis is mainly accredited to the two foremost components: toxins and capsule. Virulence component of B.anthracis includes protective antigen (PA) which plays a vital role in pathogenesis, virulence protein edema factor (EF) and lethal factor (LF). This search for novel therapeutic strategies that attack the proteins involved in the pathogenesis of anthrax and may potentially supplement antimicrobials being investigated. Currently, extensive attempts are in progress to develop novel helpful therapies to all of the virulence components: lethal factor, protective antigen, edema factor and the capsule of B. anthracis. This review discusses the potential anthrax therapeutic, prophylactic measures and diagnostic applications based on recent patents' prospects.
INTRODUCTION
Bacillus anthracis is the responsible microbe for anthrax infection [1] . The microbe has a single chromosome, along with two large extra-chromosomal plasmids, pXO1 (182 kb) and pXO2 (96 kb), that are indispensable for its full virulence [2] . The pXO1 plasmid has the genes that code the three anthrax exotoxin components: protective antigen having a size of 83kDa lethal factor of 89kDa and edema factor of 90kDa. Plasmid pXO2 encodes proteins that make the unique poly-D-glutamic acid capsule which confers resistance to phagocytosis [3] . There are four types of anthrax defined by the route of spore entry into the body: cutaneous, gastrointestinal, injectional and inhalational anthrax [1, 4] . As reported in the literature, spores are phagocytosed by macrophages and dendritic cells that act as a 'Trojan horse' to carry them from peripheral location to local lymph nodes where they develop to turn into toxin-producing vegetative bacteria [5] . Recent studies have revealed a fast restricted germination event [6, 7] , suggesting the bacteria conquer innate immunity, ensuing in systemic infection, a mechanism known as a 'jailbreak' [8] .
The death rate from untreated inhalational anthrax reached 100% and the expenses associated with a B. anthracis bioterrorist attack have been estimated at over $26 billion per 100,000 persons exposed [9, 10, 11] . Research to employ the Bacillus anthracis as a biowarfare is approximately 80 years *Address correspondence to this author at the Department of Biotechnology, Jaypee Institute of Information Technology, A-10, Sector-62, NOIDA-201307, Uttar Pradesh, India; Tel: + (91)-120-2400973; Fax: + (91)-120-2400986; E-mail: ckj522@yahoo.com old and a number of nations are supposed to have weaponized anthrax [12] . Current available treatment of anthrax includes lengthened treatment of antibiotics [13] . During the bioterror attack in the USA in 2001, antibiotic prophylaxis was given to individuals suspected to have been exposed to anthrax.
The drugs available for treatment of anthrax include: doxycycline, amoxicillin and ofloxacin or ciprofloxacin, penicillin G, specified for minimum duration of 60 days. These are effectual in death of bacteria, however these drugs are not capable of taking out free toxins from the blood stream [13, 14] .
Louis Pasteur was the first one to develop vaccine for anthrax using attenuated strain of B. anthracis. In the United States, MDPH-PA or MDPH-AVA or Anthrax Vaccine Adsorbed (AVA), available in the market as BioThrax is the only FDA approved vaccine [15] . Measures to prevent anthrax infection after exposure include vaccination, decontamination, and prophylactic treatment. Vaccination is recommended as part of post exposure treatment by the CDC; however, this is not a licensed use of this vaccine. This present anthrax vaccine targeting PA needs repetitive dosage and required approximately 4 weeks for generation of anti-PA protective titers. Limitation of vaccination is due to small incubation time and speedy disease development. Therefore; there exists a requirement for new and improved therapies to treat the anthrax.
Currently, passive immunization through protecting antibodies highlights a striking alternative to present after exposure treatment of anthrax as it can offer fast and extensive protection [15] . At present FDA approved Raxibacumab is the only monoclonal antibody available for the treatment of inhalational anthrax, since 2012 [14, 15] where it is used as part of a combination regimen with appropriate antibiotic drugs and has been currently recommended for non availability of other treatments for anthrax.
THE ANTHRAX TOXIN COMPONENTS
The three parts of the anthrax exotoxin, PA, LF, and EF, are separately non-toxic, but they come together to form the two major virulence factors of B. anthracis, edema toxin (ET, composed of EF + PA) and Lethal toxin (LT, composed of LF + PA) [16] . PA helps in the cellular binding and LF and EF act as the catalytic component of the toxins. B. anthracis release PA during infection, PA connects to its receptor's protein on host cells and is proteolytically activated by furin into the free N-terminal fragment PA20 and the receptor-bound C-terminal fragment PA63 Fig. (1) liberation of PA20 from PA63 stop the steric obstruction and activate PA63 to form a heptamer or octamer structure proficient for LF/EF binding [17, 18] . Residues situated on nearby PA63 monomers act as the binding sites for LF/EF. [17] . Each PA63 octamer and heptamer attach to four or three LF molecules or EF, correspondingly [17] . The PA63 oligomer/LF and/or EF complex is then entered using a receptor-mediated endocytic pathway [18] . Acidic conditions bring the exchange of the PA63 oligomer pre-pore to a proteinconducting channel in the endosomes through which LF and EF are transported into the cytoplasm of the cells [19, 20] . Since PA63 oligomerization activates receptor-mediated endocytosis, merely the EF/LF-binding competent PA63 oligomer but not cell surface-bound PA monomer, is able to get inside the cell.
ANTHRAX TOXIN RECEPTORS
Tumor endothelium marker 8 (TEM8), known as anthrax toxin receptor 1, and CMG2, also called as anthrax toxin receptor2 were recognized as receptors that facilitate anthrax toxin entrance into host cells [21, 22] . CMG2 and TEM8 are homologous cell surface proteins having an extracellular von Willebrand factor A (vWA) domain accountable for binding to PA as well as to their natural ligands. As TEM8 and CMG2 arbitrate receptor-driven toxin enter into the cell, it is hypothesized that they may have a similar function as physiologic receptors.
PROTEOLYTIC ACTIVATION OF PA
Action of anthrax toxins depends upon the proteolytic processing allowance of PA to PA63. It has been reported that PA can also be activated by unknown proteases in the plasma of animals, resulting in circulating PA63 oligomers [23] . Hence, it is supposed that PA proteolytic activation and cell surface binding are two independent processes. Before binding to receptors proteins the soluble PA63 oligomer and the effectors proteins LF and EF may bring together a toxin complex [24] . 
ESSENTIAL ROLES OF ANTHRAX TOXINS IN AN-THRAX INFECTION
B. anthracis must conquer the important scavenger functions of the host innate immunity, to set up a successful infection [25] . Presence of several current studies has shown that anthrax LT and ET not only effect tissue damage and lethality at delayed stages of infection but also take part in impairing the host innate immune response at the initial stage of infection too.
THE ROLES OF ANTHRAX TOXINS IN THE EARLY STAGE OF ANTHRAX INFECTION
Anthrax toxin-based vaccines can proficiently shield experimental animals from B. anthracis infections, which show that anthrax toxins are important virulence factors at the initial stage of anthrax infection [25] . A latest study by means of encapsulated virulent B. anthracis strains recommended an important role for ET in B. anthracis distribution early in infections [26] . Although, the mechanisms behind the impact of the toxins on the innate immune system is not clear till now, both LT and ET have been reported to disturb the normal functions of neutrophils, macrophages, dendritic cells, mast cells, and other myeloid cells [25, 26] .
THE ROLES OF ANTHRAX TOXINS IN LATE STAGES OF INFECTION
Toxins of anthrax not only perform major roles in initiation of anthrax infection but are also accountable for host lethality at the later stage of infection. Although B. anthracis can be effectively removed by antibiotic treatment, the toxins injected into circulation may still cause host death [26] . Review has proposed that LT was exposed to stimulate hypoxia-mediated lethality and toxicity owing to its effects on many tissues viz. heart, endothelium in many animal models [26] . ET was also shown to induce wide tissue damage and lethality [54, 84] . Current review exposes that B. anthracis has evolved to use LT and ET to persuade host lethality with the help of damaging minimum of 2 distinct vital systems, the liver and the cardio-vascular system.
GENERAL DRUG RESISTANCE IN FOLATE BIO-SYNTHESIS
Currently, the mechanism of resistance of anthrax drug is not completely understood [27] . Trimethoprim is the drug that is no more effective against bacillus anthracis infections. It acts on the dihydrofolate reductase (DHFR), an enzyme involved in the folate pathway. This enzyme is responsible for the conversion of dihydrofolate to tetrahydrofolate along with nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor. Active sites of DHFR include acidic residue (generally Asp or Glu) at one end of a large hydrophobic pocket [28] . Present antifolates include a diaminopyrimidine or s-triazine pharmacophore that forms hydrogen bonds with the acidic residue and anchors the molecule in the pocket. Leu 29, Val 32, Ile 51 and Phe 96 form vander Waals bonds with the substrate and inhibitors and are the main hydrophobic residue in the active site.
PROPHYLACTIC MEASURES INVOLVED IN THE EFFECTIVE TREATMENT OF B. ANTHRACIS

Drugs Available for Anthrax
Bacllus anthracis is sensitive to many antibiotics including ciprofloxacin, doxycycline, erythromycin, vancomycin, and penicillin [29] . However, owing to the rapid course of the disease, even with intense antibiotic and supportive therapies, mortality rates for inhalational anthrax are still high. This is presumably due to the continuing effects of the anthrax toxins [30] . Ciprofloxacin is a drug that binds to DNA topoisomerase 4 subunit A, whereas doxycycline inhibits the action of 30S ribosomal protein. Erythromycin binds to 50s ribosomal protein, vancomycin binds to D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan, penicillin binds to Peniciilin binding Protein 1A. Complete list of current drugs along with their drug target is shown in the Fig. (2) .
Vaccine Available for Anthrax
BioThrax (anthrax vaccine absorbed, AVA) was shown to improve survival of a patient with naturally-acquired inhalational anthrax [31] . BioThrax is thus far the only FDAlicensed anthrax toxin-based vaccine available for preexposure use. BioThrax has actually been used for postexposure prophylaxis and is recommended by the CDC Advisory Committee on Immunization Practices for use of PEP. Thus, for treatment of persons with known or suspected exposure to B. anthracis spores, the US Centers for Disease Control recommend a combination of 60 day oral antibiotic treatment with a three-dose BioThrax vaccination. BioThrax is an incompletely-defined vaccine, produced from culture filtrates of an avirulent, non-encapsulated B. anthracis strain, with PA as the major component. More defined and recombinant PA-based anthrax vaccines are currently under active development.
Monoclonal Antibodies for the Treatment Available for Anthrax
In 2012 the US FDA approved Raxibacumab, the first human monoclonal antibody against PA, for treatment of inhalational anthrax [32] . Anthrax binds to domain 4 of PA and blocks toxin binding to its receptors. Several additional human and chimpanzee monoclonal antibodies against PA, LF, and EF are in clinical development [33] . Recently, a fusion of the extracellular domain of human CMG2 and human immunoglobulin G (IgG) Fc fragment (CMG2-Fc) was shown to be effective in neutralizing PA and protecting rabbits from B. anthracis infection [34] . Adefovir dipivoxyl, an ATP analog used for hepatitis B treatment in humans, was found to be an effective inhibitor of EF in vitro and in some in vivo models [35, 36, and 37] . One obvious advantage of these small-molecule inhibitors of LF and EF is that they should be effective against the toxins that have already gained entry into the cytosol of target cells. 
CURRENT PATENTS ON DIAGONOSIS AND THERAPEUTICS OF ANTHRAX
Studies revealed the important therapeutics needed for anthrax treatment. The patent' analysis has been summarized in further sections Table 4 and Table 5 .
PATENTS ON DIAGNOSIS OF ANTHRAX
Some impactful and newly granted patents on diagnosis of anthrax have been discussed below: Kozel et al. described the compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. The present invention described techniques useful for diagnosis of anthrax by recognition of capsular polypeptide in serum or other biological samples [69] . Morrow et al. developed an extremely efficient technique for generating human antibodies using recall technology. This method offer high human antibody titers that are primarily of the IgG isotype along with antibodies of high specificity and affinity to desired antigens [70] . The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. This patent presents a new method for diagnosis of anthrax.
Mangold et al. described diagnostic tools and therapies using antibodies to Bacillus anthracis. Specifically; the present invention is aimed at a B. anthracis-specific monoclonal antibody that binds to the EA antigen (corresponding to the eag gene) of the S-layer (surface layer) of spores [67] . This monoclonal antibody possibly will be used in a variety of application, including specifically detecting and diagnosing B.anthracis. Antibodies can be incorporated into detection kits and such detection kits can distinguish anthrax spores from non-pathogenic varieties of spores. Vivekananda et al. invention described the methods of using nucleic acid ligands against anthrax spores, compositions comprising of anthrax specific nucleic acid ligands and ultimately leads to use the ligands for detection of anthrax spores [65] .
Myers et al. described methods and compositions capable of quickly transferring antibody-mediated protection against lethal infections of B. anthracis in an animal [64] . The present invention method includes providing plasma from donors, having a measureable level of immunologically active immunoglobulin against anthrax; and administering a predetermined quantity of said plasma product to the animal, wherein an antibody mediated protection against lethal infections of B. anthracis is elicited. Boyer et al. documented diagnosis methods presently available for anthrax and their limitation of taking very long time to produce the results. Boyer et al. present invention that decreases diagnosis time to approximate four hours providing same day identification of anthrax [71] . The presented invention isolates and concentrates lethal factor and lethal toxin from nearly any biological sample. By measuring endopeptidase activity of lethal factor the current invention amplifies output signals result in the production of reliable detection of picomolar concentrations of lethal factor. Georgiou et al. described a method for diagnosis of anthrax with the help of an affinity matured antibody or a monoclonal antibody [63] . Morrow et al. developed an efficient method for generating human antibodies and use of these antibodies for detection of anthrax [62] .
Levy Joshua stated a method of treatment of severe anthrax infection particularly inhalation pneumonia or gastrointestinal anthrax antigen by the passive transfer to infected patients of plasma or plasma fractionated derivatives, such as gamma globulins or antibodies, monoclonal with high titer neutralizing antibodies against Bacillus anthracis or its toxins [57] . Xiong et al. state a new formula for treating anthrax by inhibiting lethal factor. This invention further discussed the use of the compounds of formula to treat other conditions related to an anthrax infection [58] .
PATENTS ON THERAPEUTICS OF ANTHRAX
Some impactful and newly granted patents on therapeutics of anthrax have been discussed below:
Dreier et al. presented a method for treating an anthrax infection by proposing a new chemical moiety. Bogoch et al. invented isolated peptides of the Bacillus anthracis Anthrax toxin LF Protein pX01-107, antibodies specific for the peptides are disclosed [77] . Morrow et al. described a highly proficient technique for generating human antibodies using recall technology. A formulation for treating anthrax infection utilizing a binding agent that inhibits the assembly of the PA63 heptamer is disclosed in this invention [82] .
Chen et al. presented invention recognizes monoclonal antibodies that neutralize anthrax protective antigen (PA) toxin [84] . The invention offers new method for treating anthrax. Edward et al. presented invention disclosed systems for targeted deliverance of a compound to a target cell that over-expresses two distinct proteinases [85] . Particularly, two different protective antigen proteins, having a cleavage site recognized by a distinct proteinase are administered in combination with a compound that contains a protective antigen binding site.
Resistance is reported against many drugs belonging to different classes. Current anthrax vaccines have high expenditure of production and the need for repetitive dosing. With major progress and development of research and patent literature over the years, the role of monoclonal antibodies in anthrax therapeutics has a great potential. Several therapeutically useful anti-PA, anti-LF, anti-EF are available, to each of the virulence components viz. protective antigen (PA), lethal factor (LF) and edema factor (EF). This review summarizes the several therapeutics, their mechanism, prophylactic treatments available for anthrax and explains the potential therapeutic benefits of a cocktail of mAbs, specific to different epitopes or different virulence factors. Currently;
CURRENT & FUTURE DEVELOPMENTS
based on patent analysis, monoclonal antibodies targeting anthrax toxins have been reported as recent therapy against anthrax. 
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